19 December 2019
Visiongain’s new report the Clinical Laboratory Tests Market Report 2019-2029: Forecasts by Type (Medical Microbiology, Clinical Chemistry, Hematology, Cytology, Food Intolerance Test, Human and Tumor Genetics, Drug Abuse Testing, Other Esoteric Tests), by Service Provider (Hospital-Based Laboratories, CROs, Others), plus analysis of leading companies indicates that the global Clinical Laboratory Tests market will attain $363 billion revenue by 2029.
Global Clinical Laboratory Tests market is expected to grow on account of growing geriatric population and it is anticipated that growing investments in target diseases epidemiology such as CVDs and diabetes will further boost market growth over the forecast period. The market is expected to grow at a healthy CAGR of 7.6% over the projected period. Growing unhealthy food consumption coupled with growth in obesity levels has led to the growth of numerous chronic diseases such as heart diseases, diabetes and high blood pressure among others. Also, rising awarenessabout the importance of clinical laboratory tests in the delivery of quality health care among patients and healthcare professionals are some of the factors which are anticipated to fuel the growth of clinical laboratory tests market over the forecast period.
In 2019, hospital-based clinical laboratory tests service providers accounted for the majority of market share, owing to the growing demand for early disease detection in combination with emerging infectious diseases. Hospital-based laboratories provide extensive services ranging from key testing, specialty testing to laboratory management services which is expected to spur the growth of clinical laboratory tests market.
In 2019, North America Clinical Laboratory Tests market accounted for more than 35% of overall market share. Strong economic growth followed by the presence of major diagnostic technologies companies is expected to increase Clinical Laboratory Tests market penetration over the forecast period. Asia Pacific is expected to grow at the highest CAGR owing to the presence of untapped opportunities and growth in scientific research in developing economies like India, Japan, and China. Similar trends will offer lucrative growth for clinical laboratory tests market in coming years.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.
09 September 2020
The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.